Peptide Research
GLP-1 Discontinuation and Weight Regain: What Published Trials Show
⚠ FOR EDUCATIONAL AND SCIENTIFIC REFERENCE PURPOSES ONLY. THIS ARTICLE SUMMARISES PUBLISHED CLINICAL LITERATURE AND IS NOT MEDICAL ADVICE.
Quick answer: Randomised withdrawal trials consistently report substantial weight regain after GLP-1 receptor agonist discontinuation. In the STEP-1 extension, participants regained a...
THE BIG PEPTIDE SHIFT: WHAT’S CHANGING, WHAT TO EXPECT, AND WHAT IT MEANS FOR YOU
THE BIG PEPTIDE SHIFT: WHAT'S CHANGING, WHAT TO EXPECT, AND WHAT IT MEANS FOR YOU
14 Peptides May Return to Legal Compounding. Here's Everything You Need to Know — In Plain English.
FOR RESEARCH AND EDUCATIONAL PURPOSES ONLY
This document provides educational information about emerging peptide compounding regulations and...
WHY DID PEPTIDE SCIENCES SHUT DOWN OVERNIGHT?
WHY DID PEPTIDE SCIENCES SHUT DOWN OVERNIGHT?
The inside story: FDA enforcement, pharmaceutical litigation, and the quality failures behind a $7.4M/month closure
Quick answer: Peptide Sciences, the largest U.S. gray-market research peptide vendor, shut down abruptly in March 2026 amid FDA scrutiny and pharmaceutica...
GLP-1 Receptor Agonists and Sleep Apnea: What the SURMOUNT-OSA Trials Show
⚠ FOR EDUCATIONAL AND SCIENTIFIC REFERENCE PURPOSES ONLY. THIS ARTICLE SUMMARISES PUBLISHED CLINICAL LITERATURE AND IS NOT MEDICAL ADVICE.
Quick answer: The SURMOUNT-OSA phase 3 programme — two 52-week randomised, double-blind, placebo-controlled trials published in the New England Journal of Medicine — reported that tir...
GLP-1 Receptor Agonists and Liver Disease: What the MASH Trials Show
⚠ FOR EDUCATIONAL AND SCIENTIFIC REFERENCE PURPOSES ONLY. THIS ARTICLE SUMMARISES PUBLISHED CLINICAL LITERATURE AND IS NOT MEDICAL ADVICE.
Quick answer: The phase 3 ESSENCE trial, published in the New England Journal of Medicine, reported that once-weekly semaglutide 2.4 mg produced resolution of steatohepatitis without ...
GLP-1 Receptor Agonists and Kidney Disease: What the FLOW Trial Shows
⚠ FOR EDUCATIONAL AND SCIENTIFIC REFERENCE PURPOSES ONLY. THIS ARTICLE SUMMARISES PUBLISHED CLINICAL LITERATURE AND IS NOT MEDICAL ADVICE.
Quick answer: The FLOW trial — the first dedicated kidney outcomes trial for a GLP-1 receptor agonist, published in the New England Journal of Medicine in 2024 — reported a 24% reduct...
Oral GLP-1 Receptor Agonists: Orforglipron, Oral Semaglutide and the Trial Data
⚠ FOR EDUCATIONAL AND SCIENTIFIC REFERENCE PURPOSES ONLY. THIS ARTICLE SUMMARISES PUBLISHED CLINICAL LITERATURE AND IS NOT MEDICAL ADVICE.
Quick answer: Two oral GLP-1 receptor agonists have now reached the US market through separate routes. Oral semaglutide 25 mg — a peptide formulation requiring fasted administration —...
Antimicrobial Peptides (AMPs) in Research: Mechanisms and Pipeline
⚠ FOR LABORATORY RESEARCH AND EDUCATIONAL PURPOSES ONLY — NOT FOR HUMAN OR ANIMAL CONSUMPTION.
Quick answer: Antimicrobial peptides (AMPs), also called host-defense peptides, are short peptides that many organisms produce as part of innate immunity against bacteria, viruses, and fungi. Because they disrupt microbial memb...
Collagen Peptide Research: Pro-Hyp, GHK-Cu and Matrix Pathways
⚠ FOR LABORATORY RESEARCH AND EDUCATIONAL PURPOSES ONLY — NOT FOR HUMAN OR ANIMAL CONSUMPTION.
Quick answer: Collagen peptide research covers two distinct areas that are often confused. The first is dietary hydrolysed collagen, where studies have examined whether specific fragments such as Pro-Hyp survive digestion. The ...
GLP-1 Weight Loss and Body Composition: What Research Shows About Lean Mass
⚠ FOR EDUCATIONAL AND SCIENTIFIC REFERENCE PURPOSES ONLY. THIS ARTICLE SUMMARISES PUBLISHED CLINICAL LITERATURE AND IS NOT MEDICAL ADVICE.
Quick answer: Body composition studies report that lean soft tissue accounts for roughly 20–40% of total weight reduction during GLP-1 receptor agonist treatment, measured by DXA. How...